UCL researchers found that suppressive immune cells build up months or years before lung cancer forms, tracked them with prototype blood tests and halved tumor formation in mice with a drug.
Memorial Sloan Kettering researchers found that the signaling molecule MEK drives T cells into exhaustion by making them overspend energy. Blocking it helped the cells persist in lab and animal models. MEK inhibitors are already approved drugs, but no patient has been tested yet.
In a University of Calgary trial, 82% of 24 glioblastoma patients given high-dose niacin with standard treatment had no cancer progression after six months, against about 54% in earlier studies. The trial is small and has no control group.
A world-first clinical trial has found that CAR T-cell therapy sharply reduced disease activity in all six patients with severe rheumatoid arthritis, with three remaining in remission without arthritis medication.